BPG is committed to discovery and dissemination of knowledge
Retrospective Study
©The Author(s) 2025.
World J Gastrointest Surg. Nov 27, 2025; 17(11): 111619
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.111619
Table 1 Comparison of clinical data between the two groups of patients
Factors
Bleeding group (n = 29)
Non-bleeding group (n = 149)
t/χ2
P value
Age (years)61.21 ± 12.3560.55 ± 11.560.2770.782
Sex, n (%)0.0350.852
    Male16 (55.17)85 (57.15)
    Female13 (44.83)6442.95
Diabetes, n (%)1.0740.300
    Yes6 (20.69)45 (30.20)
    No23 (79.31)104 (69.80)
History of chronic kidney disease, n (%)1.5420.214
    Yes6 (20.69)18 (12.08)
    No23 (79.31)131 (87.92)
Preoperative anemia, n (%)0.0130.910
    Yes5 (17.24)27 (18.12)
    No24 (82.76)122 (81.88)
Tumor size [cm; n (%)]12.010< 0.001
    < 310 (34.48)47 (31.54)
    ≥ 319 (65.52)102 (68.46)
Infiltration depth, n (%)1.7170.424
    M126 (89.66)122 (81.88)
    M23 (10.34)20 (13.42)
    M30 (0.00)74.70
Tumor location, n (%)0.6560.720
    Upper esophagus10 (34.48)41 (27.52)
    Middle esophagus5 (17.24)32 (21.48)
    Lower esophagus14 (48.28)76 (51.00)
Tumor morphology, n (%)2.6750.263
    Uplift13 (44.83)84 (56.38)
    Depression13 (44.83)59 (39.60)
    Flat3 (10.34)6 (4.03)
Intraoperative bleeding, n (%)6.6220.010
    Yes8 (27.59)17 (11.41)
    No21 (72.41)132 (88.59)
Operation time (minute)50.10 ± 3.3249.22 ± 2.95
Postoperative anticoagulant use, n (%)0.5430.461
    No17 (58.62)98 (65.77)
    Yes12 (41.38)51 (34.23)


Write to the Help Desk